Printer Friendly

STOUGHTON NAMED TO HEAD SMITHKLINE BEECHAM'S CLINICAL LABORATORY BUSINESS

 STOUGHTON NAMED TO HEAD SMITHKLINE BEECHAM'S
 CLINICAL LABORATORY BUSINESS
 PHILADELPHIA, May 19 /PRNewswire/ -- W. Vickery Stoughton, chief executive officer of Duke University Hospital, has been appointed president of SmithKline Beecham Clinical Laboratories, it was announced today by Robert Bauman, chief executive SmithKline Beecham, (NYSE: SBH).
 Stoughton, 46, will take over in July as head of SmithKline Beecham's clinical laboratory unit, the largest clinical laboratory network in the United States with 1991 sales of $1 billion.
 Stoughton succeeds Harry Groome, who earlier this year was named chairman of SmithKline Beecham's worldwide consumer brands business.
 "Vick is extraordinarily qualified to direct our clinical laboratory business in a period of opportunity and change," Bauman said. "His proven leadership, extensive healthcare background and experience and his first-hand knowledge of key customers, including major medical centers and individual physicians, will be excellent assets in his new assignment."
 Author of a number of articles on healthcare, Stoughton has served as chief executive officer of Duke University Hospital and vice chancellor for health affairs at Duke since 1991. From 1987 to 1991 he served as president and chief executive officer of the Toronto Hospital, and from 1981 to 1987 he served as president and chief executive officer of Toronto General Hospital which was created by the merger of Toronto General Hospital and Toronto Western Hospital.
 A graduate of the University of St. Louis, Stoughton received his MBA from the University of Chicago and did postgraduate work at Massachusetts Institute of Technology. He began his career with several management positions at Brigham and Women's Hospital in Boston.
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, biologicals, over-the-counter medicines, health related consumer brands and clinical laboratory testing services. SB markets its more than 300 products in more than 130 countries.
 /delval/
 -0- 5/19/92
 /CONTACT: Jeremy Heymsfeld, 215-751-5166, or Richard Williams (financial), 215-751-7002, both of SmithKline Beecham/
 (SBH) CO: SmithKline Beecham ST: Pennsylvania IN: MTC SU: PER


JS -- PH004 -- 1650 05/19/92 08:44 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1992
Words:338
Previous Article:ATLANTIC RESTAURANT VENTURES, INC. REPORTS THIRD QUARTER EARNINGS
Next Article:GZA GEOENVIRONMENTAL TECHNOLOGIES ANNOUNCES STOCK REPURCHASE PROGRAM
Topics:


Related Articles
TORRENZANO TO HEAD SMITHKLINE BEECHAM CORPORATE AFFAIRS
GROOME NAMED TO LEAD SMITHKLINE BEECHAM'S CONSUMER BRANDS BUSINESS; HUNTER TO RETIRE
GROOME ELECTED TO SMITHKLINE BEECHAM BOARD
GARNIER ELECTED TO SMITHKLINE BEECHAM BOARD
ALAIN GOMEZ RESIGNS FROM SMITHKLINE BEECHAM BOARD OF DIRECTORS
JP GARNIER APPOINTED CHIEF OPERATING OFFICER OF SMITHKLINE BEECHAM; KEY STEP IN HEALTHCARE INTEGRATION
SMITHKLINE BEECHAM STRENGTHENS COMMITMENT TO INTEGRATED HEALTHCARE; CREATES SB HEALTHCARE SERVICES UNIT TO BE HEADED BY DR. TADATAKA YAMADA,...
BROWNE APPOINTED TO SMITHKLINE BEECHAM BOARD OF DIRECTORS
SmithKline Beecham Names George Poste Chief Science and Technology Officer
SmithKline Beecham Appoints Dr. David C. U'Prichard Chairman, Research And Development, Pharmaceuticals

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters